§ Implementation of Wellgistics’ proprietary EinsteinRx AI hub anticipated to facilitate automated prescription fulfillment optimization for manufacturers, pharmacies, physicians, patients, and payers
§ Datavault’s enabling IP provides smart contracts barrier to entry in the $4.9 trillion US healthcare market[2]
§ Wellgistics PharmacyChain ‘Health Data Railroad’ is the culmination of its revolutionary, Web 3.0 integrated smart contracts distribution infrastructure
§ PwC estimates $1 trillion opportunity to shift healthcare spending towards a digital-first, proactive, and personalized system[3] of care that minimizes administrative burden
PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) — via IBN – DataVault AI, Inc. (Nasdaq: DVLT) (“Datavault” or the “Company”), leading the way in AI data experience, valuation, and monetization, today announced it has exclusively licensed its proprietary smart contracts intellectual property to Wellgistics Health, Inc. for integration into its PharmacyChain smart contract and EinsteinRx initiatives.
Tampa, Florida-based Wellgistics Health (Nasdaq: WGRX) is a physical and technology pharmacy-enabling health IT company that specializes in optimizing the delivery of medications from manufacturers to patients. The objective of its PharmacyChain is to fully digitize the tracking of prescription drugs from script to fulfillment, inclusive of all electronic medical records, diagnostic, and health information needed to make healthcare decisions. This is designed to ensure the right drug gets to the right patient at the right time, with the right recommendations for safe and effective use.
With the completion of Wellgistics Health’s EinsteinRx artificial intelligence-enabled hub that integrates all of its IT infrastructure with its physical infrastructure, which includes over 6,500 independent pharmacies nationwide and its own in-house pharmacy (physical/online), Wellgistics is poised to be able to integrate PharmacyChain smart contracts to close the loop, which otherwise forces drug manufacturers to pay significant rebates to pharmacy benefits managers (PBMs) associated with national insurance companies.
Read more on wallstreet:online
